Medical management of atrial fibrillation

Current Cardiology Reports

Volumn 8, Issue 5, 2006, Pages 323-329

  Hersi, Ahmad ^b   Wyse, D George ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIVITAMIN K; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENALAPRIL; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; IRBESARTAN; MAGNESIUM SULFATE; METOPROLOL; PROPAFENONE; RSD 1235; SHORT ACTING DRUG; SOTALOL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; WARFARIN; XIMELAGATRAN;

ANGINA PECTORIS; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; BLEEDING; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; CARDIOVERSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DOSE REGIMEN; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART PROARRHYTHMIA; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; LIVER TOXICITY; LUNG TOXICITY; PERIPHERAL NEUROPATHY; REVIEW; SKIN DISCOLORATION; STROKE; TACHYCARDIA; THYROID DISEASE; TORSADE DES POINTES; URINE RETENTION; XEROSTOMIA;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; ELECTRIC COUNTERSHOCK; FIBRINOLYTIC AGENTS; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS;

EID: 33749044221     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-006-0070-6     Document Type: Review

References (23)

1. Boriani G, Diemberger I, Biffi M, et al.: Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004, 64:2741-2762.
2. Roy D, Rowe BH, Stiell IG, et al.: A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004, 44:2355-2361.
3. Miller MR, McNamara RL, Segal JB, et al.: Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm. J Fam Prac 2000, 49:1033-1046.
4. Singh BN, Singh SN, Reda DJ, et al.: Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) investigators. N Engl J Med 2005, 352:1861-1872.
5. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. A report of the American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee of Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with North American society of Pacing and Electrophysiology. Eur Heart J 2001, 22:1852-1923.
6. Pritchett EL, Page RL, Connolly SJ, et al.: Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. J Am Coll Cardiol 2000, 35:794-802.
7. Touboul P, Brugada J, Capucci A, et al.: Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003, 24:1481-1487.
8. Olshansky B, Rosenfeld LE, Warner AL, et al.: The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004, 43:1201-1208.
9. Wyse DG: Rate control vs rhythm control strategies in atrial fibrillation. Prog Cardiovasc Dis 2005, 48:125-138.
10. Wyse DG, Simpson CS: Rate control versus rhythm control - decision making. Can J Cardiol 2005, 21(Suppl B):15B-8B.
11. Hersi A, Wyse DG: Management of atrial fibrillation. Curr Probl Cardiol 2005, 30:175-233.
12. Nieuwlaat R, Capucci A, Camm AJ, et al.: Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Euro Heart J 2005,26:2422-2434.
13. Gage BF, Van Walraven C, Pearce L, et al.: Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287-2292.
14. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
15. Atrial Fibrillation Investigators: Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
16. DiMarco JP, Flaker G, Waldo AL, et al.: Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005, 149: 650-656.
17. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691-1698.
18. Albert GW, Diener HC, Frison L, et al.: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293:690-698.
19. Lozano H, Conde C, Florin T, et al.: Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2005, 2:1000-1007.
20. Ehrlich JR, Hohnloser SH, Nattel S: Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006, 27:512-518.
21. McMurray J, Køber L, Robertson M, et al.: Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005, 45:525-530.
22. Wachtell K, Lehto M, Gerdts E, et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712-719.
23. Alboni P, Botto GL, Baldi N, et al.: Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004, 351:2384-2391.